Literature DB >> 9555685

Cardiovascular disease in women: gender-specific aspects of hypertension and the consequences of treatment.

M J Legato1.   

Abstract

The epidemiology, clinical course, response to treatment, and ultimate outcome of essential hypertension vary as a function of gender. Three early trials on hypertension reported an increase in all-cause mortality in treated white women compared with black women or with men of both races. Later studies, however, suggest that drug therapy has similar and beneficial effects in hypertensive men and women. Women may tolerate hypertension better than do men. Diastolic hypertension correlates with higher mortality from coronary artery disease in men than in women. Special considerations apply to treating the hypertensive woman. Use of oral contraceptives may precipitate or accentuate the problem. In contrast, in the postmenopausal female, estrogen replacement may actually improve hypertension, via several mechanisms. These include the impact of the hormone on vasomotricity, its enhancement of baroreceptor sensitivity, and its impact on the hyperinsulinemia characteristic of menopause. Treatment of hypertension must be individualized with respect to gender. More data on the consequences of treatment of women with hypertension are needed, particularly longterm studies to assess the impact of treatment on mortality.

Entities:  

Mesh:

Year:  1998        PMID: 9555685     DOI: 10.1089/jwh.1998.7.199

Source DB:  PubMed          Journal:  J Womens Health        ISSN: 1059-7115            Impact factor:   2.681


  2 in total

1.  Evaluation of the effect of systolic blood pressure and pulse pressure on cognitive function: the Women's Health and Aging Study II.

Authors:  Sevil Yasar; Jean Y Ko; Stephanie Nothelle; Michelle M Mielke; Michelle C Carlson
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

2.  Gender and age differences in lifestyle factors related to hypertension in middle-aged civil service employees.

Authors:  Yoko Hori; Hideaki Toyoshima; Takaaki Kondo; Koji Tamakoshi; Hiroshi Yatsuya; ShanKuan Zhu; Takashi Kawamura; Junji Toyama; Noboru Okamoto
Journal:  J Epidemiol       Date:  2003-01       Impact factor: 3.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.